FDA Modernization Act 3.0
Latest action · Feb 9, 2024 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 6, 2024
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
FDA Modernization Act 3.0
This bill requires the Food and Drug Administration (FDA) to establish a process that supports nonclinical testing methods for drug development that do not involve the use of animals.
Specifically, the FDA must establish a pathway by which entities may apply to have nonclinical testing methods approved for use in a particular context. Qualifying methods must be intended to replace or reduce animal testing and to either improve the safety and efficacy of nonclinical testing or reduce the time to develop a drug. The FDA must issue its decision within 180 days of receiving an application. The FDA must also prioritize the review of applications for drugs that are developed using an approved nonclinical testing method.
The FDA must annually post a report on its website that summarizes the results of the bill's implementation, including the number of applications received, types of methods that were approved, and the estimated number of animals saved as result of these methods.
Cosponsors 46
Members who signed on, in the order they did. Signatures ran from Feb 6, 2024 to Dec 17, 2024; 10 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-PA | Brian K. Fitzpatrick | Original | Feb 6, 2024 |
| R-TX | Dan Crenshaw | Original | Feb 6, 2024 |
| R-TN | Diana Harshbarger | Original | Feb 6, 2024 |
| R-TX | Lance Gooden | Original | Feb 6, 2024 |
| R-FL | Michael Waltz | Original | Feb 6, 2024 |
| D-CA | Nanette Diaz Barragán | Original | Feb 6, 2024 |
| D-CT | Rosa L. DeLauro | Original | Feb 6, 2024 |
| D-LA | Troy A. Carter | Original | Feb 6, 2024 |
| R-TX | Troy E. Nehls | Original | Feb 6, 2024 |
| R-FL | Vern Buchanan | Original | Feb 6, 2024 |
| R-CA | David G. Valadao | Feb 13, 2024 | |
| D-CO | Joe Neguse | Feb 14, 2024 | |
| D-NC | Donald G. Davis | Feb 23, 2024 | |
| R-FL | Gus M. Bilirakis | Feb 23, 2024 | |
| D-NJ | Josh Gottheimer | Feb 29, 2024 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Feb 6, 2024 |
| Health Subcommittee | Referred Feb 9, 2024 |
Actions 3
Everything that happened, newest first.
- Feb 9, 2024Referred to the Subcommittee on Health.
- Feb 6, 2024Introduced in House
- Feb 6, 2024Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 170, no. 21, February 6, 2024, page H503.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 5046 | FDA Modernization Act 3.0 | Related bill | Dec 16, 2024 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.
- Short Title(s) as Introduced
- FDA Modernization Act 3.0
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Animal protection and human-animal relationships
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Government information and archives
- Health
- Internet, web applications, social media
- Prescription drugs
Text 1
Each version as it was printed, newest first.
- Feb 6, 2024Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.